Journal
VACCINE
Volume 21, Issue 11-12, Pages 1187-1194Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S0264-410X(02)00554-6
Keywords
Listeria monocytogenes; recombinant vaccine; virulence; antigen loss
Categories
Funding
- NCI NIH HHS [T32CA09140] Funding Source: Medline
- NIAID NIH HHS [AI-36657] Funding Source: Medline
Ask authors/readers for more resources
Bioengineered Listeria monocytogenes can be used as a recombinant bacterial vaccine vector for the induction of strong cell-mediated immunity to passenger antigens. Listeria loses virulence after undergoing bioengineering techniques, thus decreasing its efficacy as a vaccine vector. We addressed this problem by examining the virulence, and the ability to induce CD8(+) T-cells, of Listeria monocytogenes vaccine strains before and after passaging through mice. We found that two in vivo passages are required to restore the induction of cell-mediated immunity to passenger antigens and maximum virulence to these strains. In addition, we found that after each passage, harvested bacteria must be cloned and checked for expression of the bioengineered gene to counter selection in favor of antigen loss mutants. (C) 2002 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available